Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14074027 | 0.78 | KDM4E (0.64) | KDM4ESMN1; SMN2ALDH1A1HTTMEN1 | |
| SCHEMBL612506 | 0.78 | KDM4E (1.00) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL10854795 | 0.77 | KDM4E (0.56) | KDM4ESMN1; SMN2ALDH1A1HTTMEN1 | |
| SCHEMBL16456325 | 0.76 | KDM4E (0.55) | KDM4ESMN1; SMN2ALDH1A1HTTMEN1 | |
| SCHEMBL24121692 | 0.75 | SMN1; SMN2 (0.51) | KDM4ESMN1; SMN2ALDH1A1HTTMEN1 | |
| SCHEMBL4247015 | 0.75 | KDM4E (0.64) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL14927151 | 0.75 | BRD4 (0.58) | KDM4ESMN1; SMN2ALDH1A1HTTMEN1 | |
| SCHEMBL20160225 | 0.75 | SMN1; SMN2 (0.51) | KDM4ESMN1; SMN2ALDH1A1HTTMEN1 | |
| SCHEMBL1374158 | 0.75 | KDM4E (0.64) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1187755 | 0.75 | KDM4E (0.64) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120025336-A | LIN28 inhibitors and methods of use thereof | 加利福尼亚大学董事会 | 2025-05-23 | — | — | CN | disclosed |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| US-12240854-B2 | TRAF 6 inhibitors | HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGSZENTRUM FUERGESUNDHEIT UND UMWELT (GMBH) (DE) | 2025-03-04 | — | — | US | disclosed |
| CN-115087657-B | LIN28 inhibitors and methods of use thereof | 加利福尼亚大学董事会 | 2025-01-21 | — | — | CN | disclosed |
| EP-4436955-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-118317950-A | Sulfonamide compounds for the treatment of neurological disorders | 拉里奥治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024137968-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | CAPULUS THERAPEUTICS, LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024137968-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | CAPULUS THERAPEUTICS, LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-3512852-B1 | TRAF 6 INHIBITORS | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2024-06-26 | — | — | EP | disclosed |
| EP-3512852-B1 | TRAF 6 INHIBITORS | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2024-06-26 | — | — | EP | disclosed |
| WO-2009071477-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-03-27 | — | — | US | disclosed |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-03-27 | — | — | US | disclosed |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-03-27 | — | — | US | disclosed |
| US-7294625-B2 | Pyrazole compounds | UBE INDUSTRIES, LTD. (JP) | 2007-11-13 | — | — | US | disclosed |
| WO-2006039325-A2 | AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | UBE INDUSTRIES, LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1553096-A1 | PYRAZOLE COMPOUNDS | Ube Industries, Ltd. (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-4826834-A | BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, CHRNA5, GABRA1 | KDM4E 1917/4885SMN1; SMN2 2079/4885ALDH1A1 1301/4885 |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | KDM4E 571/4885SMN1; SMN2 4325/4885ALDH1A1 1070/4885 |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | KDM4E 2441/4885SMN1; SMN2 84/4885ALDH1A1 3306/4885 |
| US-12240854-B2 | TRAF 6 inhibitors | TRAF2, TRAF6, TRAFD1 | KDM4E 589/4885SMN1; SMN2 1172/4885ALDH1A1 3705/4885 |
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | CNKSR1, MAPK1, MAPK3 | KDM4E 1462/4885SMN1; SMN2 4443/4885ALDH1A1 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.